Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors

Journal of Immunology

Volumn 190, Issue 11, 2013, Pages 5757-5763

  Castelli, Florence Anne ^a,b   Szely, Natacha ^a   Olivain, Alexis ^a   Casartelli, Nicoletta ^c   Grygar, Caroline ^a   Schneider, Aurélie ^a   Besse, Aurore ^a   Levy, Yves ^b,d   Schwartz, Olivier ^b,c   Maillère, Bernard ^a,b  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b Agence Natl de Rech Sur le SIDA   (France)

^c INSTITUT PASTEUR   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS VACCINE; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LIPO 5 VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CELL SPECIFICITY; CELL STIMULATION; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DONOR; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL;

AIDS VACCINES; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CONSENSUS SEQUENCE; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HLA-DR ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; VACCINES, SYNTHETIC;

EID: 84878089292     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300145     Document Type: Article

References (51)

1. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
2. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6: 207-210. (Pubitemid 30082367)
3. Flynn, N. M., D. N. Forthal, C. D. Harro, F. N. Judson, K. H. Mayer, and M. F. Para; rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
4. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, and K. Choopanya; Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671. (Pubitemid 44901996)
5. Watkins, D. I., D. R. Burton, E. G. Kallas, J. P. Moore, and W. C. Koff. 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14: 617-621. (Pubitemid 351809543)
6. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450. (Pubitemid 27509814)
7. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. Keet, J. K. Eeftinck-Schattenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181: 1365-1372.
8. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279: 2103-2106. (Pubitemid 28196353)
9. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
10. Sáez-Cirión, A., C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia, F. Boufassa, F. Barré-Sinoussi, J. F. Delfraissy, M. Sinet, G. Pancino, and A. Venet; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 104: 6776-6781.
11. Miura, T., M. A. Brockman, A. Schneidewind, M. Lobritz, F. Pereyra, A. Rathod, B. L. Block, Z. L. Brumme, C. J. Brumme, B. Baker, et al. 2009. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 83: 2743-2755.
12. Vingert, B., S. Perez-Patrigeon, P. Jeannin, O. Lambotte, F. Boufassa, F. Lemaître, W. W. Kwok, I. Theodorou, J. F. Delfraissy, J. Thèze, and L. A. Chakrabarti; ANRS EP36 HIV Controllers Study Group. 2010. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 6: e1000780.
13. Ferre, A. L., P. W. Hunt, D. H. McConnell, M. M. Morris, J. C. Garcia, R. B. Pollard, H. F. Yee, Jr., J. N. Martin, S. G. Deeks, and B. L. Shacklett. 2010. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J. Virol. 84: 11020-11029.
14. Almeida, J. R., D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce, E. Bornstein, T. E. Asher, A. Samri, A. Schnuriger, I. Theodorou, et al. 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-2485. (Pubitemid 47529331)
15. Migueles, S. A., M. S. Sabbaghian, W. L. Shupert, M. P. Bettinotti, F. M. Marincola, L. Martino, C. W. Hallahan, S. M. Selig, D. Schwartz, J. Sullivan, and M. Connors. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term non-progressors. Proc. Natl. Acad. Sci. USA 97: 2709-2714. (Pubitemid 30159236)
16. Chen, Y., R. Winchester, B. Korber, J. Gagliano, Y. Bryson, C. Hutto, N. Martin, G. McSherry, A. Petru, D. Wara, and A. Ammann. 1997. Influence of HLA alleles on the rate of progression of vertically transmitted HIV infection in children: association of several HLA-DR13 alleles with long-term survivorship and the potential association of HLA-A*2301 with rapid progression to AIDS: Long-Term Survivor Study. Hum. Immunol. 55: 154-162. (Pubitemid 27467987)
17. Julg, B., E. S. Moodley, Y. Qi, D. Ramduth, S. Reddy, Z. Mncube, X. Gao, P. J. Goulder, R. Detels, T. Ndung'u, et al. 2011. Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J. Infect. Dis. 203: 803-809.
18. Altfeld, M., E. T. Kalife, Y. Qi, H. Streeck, M. Lichterfeld, M. N. Johnston, N. Burgett, M. E. Swartz, A. Yang, G. Alter, et al. 2006. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med. 3: e403.
19. Kaufmann, D. E., P. M. Bailey, J. Sidney, B. Wagner, P. J. Norris, M. N. Johnston, L. A. Cosimi, M. M. Addo, M. Lichterfeld, M. Altfeld, et al. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78: 4463-4477. (Pubitemid 38501066)
20. Wilson, C. C., B. Palmer, S. Southwood, J. Sidney, Y. Higashimoto, E. Appella, R. Chesnut, A. Sette, and B. D. Livingston. 2001. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J. Virol. 75: 4195-4207. (Pubitemid 32410132)
21. Ramduth, D., P. Chetty, N. C. Mngquandaniso, N. Nene, J. D. Harlow, I. Honeyborne, N. Ntumba, S. Gappoo, C. Henry, P. Jeena, et al. 2005. Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses. J. Infect. Dis. 192: 1588-1596. (Pubitemid 41504694)
22. Ranasinghe, S., M. Flanders, S. Cutler, D. Z. Soghoian, M. Ghebremichael, I. Davis, M. Lindqvist, F. Pereyra, B. D. Walker, D. Heckerman, and H. Streeck. 2012. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J. Virol. 86: 277-283.
23. Gammon, G., N. Shastri, J. Cogswell, S. Wilbur, S. Sadegh-Nasseri, U. Krzych, A. Miller, and E. Sercarz. 1987. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol. Rev. 98: 53-73. (Pubitemid 17128065)
24. Assarsson, E., J. Sidney, C. Oseroff, V. Pasquetto, H. H. Bui, N. Frahm, C. Brander, B. Peters, H. Grey, and A. Sette. 2007. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J. Immunol. 178: 7890-7901. (Pubitemid 46898061)
25. Gahéry-Ségard, H., G. Pialoux, B. Charmeteau, S. Sermet, H. Poncelet, M. Raux, A. Tartar, J. P. Lévy, H. Gras-Masse, and J. G. Guillet. 2000. Multi-epitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 74: 1694-1703. (Pubitemid 30434025)
26. Launay, O., C. Durier, C. Desaint, B. Silbermann, A. Jackson, G. Pialoux, B. Bonnet, I. Poizot-Martin, G. Gonzalez-Canali, L. Cuzin, et al; ANRS VAC16 Study Group. 2007. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One 2: e725.
27. Salmon-Céron, D., C. Durier, C. Desaint, L. Cuzin, M. Surenaud, N. B. Hamouda, J. D. Leliè vre, B. Bonnet, G. Pialoux, I. Poizot-Martin, et al; ANRS VAC18 Trial Group. 2010. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 24: 2211-2223.
28. Lévy, Y., H. Gahéry-Ségard, C. Durier, A. S. Lascaux, C. Goujard, V. Meiffrédy, C. Rouzioux, R. El Habib, M. Beumont-Mauviel, J. G. Guillet, et al ANRS 093 Study Group. 2005. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19: 279-286. (Pubitemid 40396559)
29. Gahery, H., N. Daniel, B. Charmeteau, L. Ourth, A. Jackson, M. Andrieu, J. Choppin, D. Salmon, G. Pialoux, and J. G. Guillet. 2006. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22: 684-694. (Pubitemid 44061405)
30. Pialoux, G., R. P. Quercia, H. Gahery, N. Daniel, L. Slama, P. M. Girard, P. Bonnard, W. Rozenbaum, V. Schneider, D. Salmon, and J. G. Guillet. 2008. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study. Clin. Vaccine Immunol. 15: 562-568. (Pubitemid 351967085)
31. Texier, C., S. Pouvelle, M. Busson, M. Hervé, D. Charron, A. Ménez, and B. Maillère. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164: 3177-3184. (Pubitemid 30148979)
32. Texier, C., S. Pouvelle-Moratille, M. Busson, D. Charron, A. Ménez, and B. Maillère. 2001. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31: 1837-1846. (Pubitemid 32547346)
33. Rudnicka, D., J. Feldmann, F. Porrot, S. Wietgrefe, S. Guadagnini, M. C. Prévost, J. Estaquier, A. T. Haase, N. Sol-Foulon, and O. Schwartz. 2009. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J. Virol. 83: 6234-6246.
34. Wang, X. F., W. M. Cohen, F. A. Castelli, C. Almunia, B. Lethé, S. Pouvelle-Moratille, G. Munier, D. Charron, A. Ménez, H. M. Zarour, et al. 2007. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol. Immunother. 56: 807-818. (Pubitemid 46723578)
35. Delluc, S., G. Ravot, and B. Maillere. 2011. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 25: 2040-2048.
36. Buus, S., A. Sette, S. M. Colon, C. Miles, and H. M. Grey. 1987. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235: 1353-1358. (Pubitemid 17041654)
37. Zarour, H. M., B. Maillere, V. Brusic, K. Coval, E. Williams, S. Pouvelle-Moratille, F. Castelli, S. Land, J. Bennouna, T. Logan, and J. M. Kirkwood. 2002. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 62: 213-218. (Pubitemid 34074007)
38. Castelli, F. A., M. Leleu, S. Pouvelle-Moratille, S. Farci, H. M. Zarour, M. Andrieu, C. Auriault, A. Ménez, B. Georges, and B. Maillere. 2007. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins. Eur. J. Immunol. 37: 1513-1523. (Pubitemid 46939487)
39. Castelli, F. A., D. Houitte, G. Munier, N. Szely, A. Lecoq, J. P. Briand, S. Muller, and B. Maillere. 2008. Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively. Eur. J. Immunol. 38: 2821-2831.
40. Delluc, S., G. Ravot, and B. Maillere. 2010. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 116: 4542-4545.
41. Jenkins, M. K., and J. J. Moon. 2012. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J. Immunol. 188: 4135-4140.
42. Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl, and M. K. Jenkins. 2007. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213. (Pubitemid 47284919)
43. Kwok, W. W., V. Tan, L. Gillette, C. T. Littell, M. A. Soltis, R. B. LaFond, J. Yang, E. A. James, and J. H. DeLong. 2012. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J. Immunol. 188: 2537-2544.
44. Kosmrlj, A., E. L. Read, Y. Qi, T. M. Allen, M. Altfeld, S. G. Deeks, F. Pereyra, M. Carrington, B. D. Walker, and A. K. Chakraborty. 2010. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465: 350-354.
45. Diepolder, H. M., J. T. Gerlach, R. Zachoval, R. M. Hoffmann, M. C. Jung, E. A. Wierenga, S. Scholz, T. Santantonio, M. Houghton, S. Southwood, et al. 1997. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71: 6011-6019. (Pubitemid 27304939)
46. Moris, A., A. Pajot, F. Blanchet, F. Guivel-Benhassine, M. Salcedo, and O. Schwartz. 2006. Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood 108: 1643-1651. (Pubitemid 44316133)
47. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439-1443. (Pubitemid 34553083)
48. Younes, S. A., B. Yassine-Diab, A. R. Dumont, M. R. Boulassel, Z. Grossman, J. P. Routy, and R. P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198: 1909-1922. (Pubitemid 38032123)
49. Ferrando-Martínez, S., J. P. Casazza, M. Leal, K. Machmach, M. A. Muñoz-Fernández, P. Viciana, R. A. Koup, and E. Ruiz-Mateos. 2012. Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J. Virol. 86: 3667-3674.
50. Potter, S. J., C. Lacabaratz, O. Lambotte, S. Perez-Patrigeon, B. Vingert, M. Sinet, J. H. Colle, A. Urrutia, D. Scott-Algara, F. Boufassa, et al. 2007. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81: 13904-13915. (Pubitemid 350247883)
51. Geiger, R., T. Duhen, A. Lanzavecchia, and F. Sallusto. 2009. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J. Exp. Med. 206: 1525-1534.